Optimi Health announced the closing of its oversubscribed US$15 million underwritten public offering in connection with the uplisting of its common shares to the Nasdaq Capital Market. The company’s shares began trading on Nasdaq under the ticker symbol “OPTH” on May 20, 2026.
The Vancouver-based company issued 2.4 million common shares at a public offering price of US$6.25 per share, generating aggregate gross proceeds of approximately US$15 million before underwriting discounts and expenses. The underwriter also received an option to purchase up to an additional 360,000 common shares.
Joseph Gunnar & Co. acted as the sole book-running manager for the offering. The company said the proceeds will support production scaling, distribution expansion, growth initiatives in the United States, and general working capital needs.
Optimi Health focuses on manufacturing and distributing finished psychedelic drug products and continues to trade on the Canadian Securities Exchange under the symbol “OPTI.”
KEY QUOTES:
“This marks a significant milestone for Optimi. This financing provides significant strength to our balance sheet and represents the necessary working capital for the growth of our business, with ample runway to scale over the next few years. We are thrilled to welcome a number of new, high-quality investors to our Nasdaq listing, who also see the benefits of psychedelic medicine.”
Dane Stevens, Chief Executive Officer, Optimi Health
